Growth capital
Matrix Partners India backs TechMed
Matrix Partners India has invested in TechMed, a hospital lab management (HLM) pathology chain, picking up a significant minority stake. The financial details of the transaction were not disclosed.
Standard Chartered PE re-ups in Indonesia’s Navigat
Standard Chartered Private Equity (SCPE) has invested an additional $25 million in Navigat, an Indonesian company that develops independent power systems for off-grid locations. The equity commitment came in conjunction with a $279 million debt refinancing...
TVS adds to investment team, advisory board
TVS Capital has added to its senior management team by hiring Karthik Ranganathan, formerly of Baring Private Equity Partners India and ex-Ashmore Alchemy India investments director Rahul Deshpande. Both will join the firm's investment team as executive...
Portfolio: EQT Partners and Japan Home Centre
In 2010 Japan Home Centre was already a successful domestic brand but to realize its IPO ambitions it needed the right partner to guide it through a period of rapid expansion – EQT Partners
KKR agrees capital injection
Before agreeing to invest $200 million in India's Gland Pharma, KKR looked at a couple of opportunities in the injectable drugs space in the US and another in India over a period of several years. The PE firm has a long-standing interest in the industry...
Asia Awards: Operational Value Add – Yonghui Superstores
Headland Capital Partners invested in Chinese supermarket chain Yonghui Superstores in 2007 and helped turn the regional player into a sector outperformer with a national footprint
Asia Awards: Firm of the Year - KKR
KKR closed its second pan-Asia fund at $6 billion and announced investments of $1.8 billion and distributions of $1.2 billion for the year to September. Capstone, the firm’s operating unit, was a factor in each area
Adding extra: China bolt-on acquisitions
Private equity firms are exploring various strategies to help Chinese companies expand overseas. Bolt-on acquisitions are a proven approach in some markets, but that doesn’t mean they work for corporate China
ICICI Venture invests $22.4m in BTI Payments
ICICI Venture has committed INR1.4 billion ($22.4 million) to BTI Payments for a significant stake in the ATM and point-of-sales (POS) services contractor.
Temasek buys stake in India's Eros International
Temasek Holdings has made its first foray into India's Bollywood movie industry as Fullerton Fund Management - a unit of the Singapore sovereign fund - acquired a stake in local film distributor Eros International.
KKR to invest $200m in Indian drug maker Gland Pharma
KKR has agreed to buy a minority stake in Gland Pharma, an Indian injectable drugs manufacturer, for approximately $200 million. The investment facilitates the exit of Invascent Capital's Evolvence India Life Sciences Fund (EILSF).
Light at the end of the tunnel
Indian private equity has taken a beating in recent years. As the excesses of the industry’s overcrowded GP population catches up with the realities of a sluggish economy and a weakening currency, it is no surprise that fundraising has been slower in...
Australia's HighPoint Capital invests in Brand New Media
HighPoint Capital has acquired a significant minority shareholding in Brand New Media (BNM), a Sydney-headquartered business that runs digital channels for brands and broadcasters. Its partners include Seven West Media in Australia, New Zealand’s national...
CDC, IDFC co-invest in India's Green Infra
CDC Group will invest up to $25 million in Green Infra, an independent renewable power producer backed by IDFC Alternatives. The GP will add another $23.89 million as part of a $125 million financing round.
Emerging Asia to see more buyouts - AVCJ Forum
Asia will see more control deals as private equity matures in the region, but it will remain primarily a growth capital market, industry participants told the AVCJ Forum in Hong Kong.
LPs say Asian GPs lack long-term investment model - AVCJ Forum
Global institutional investors are becoming more cautious in allocating capital to Asian private equity funds, citing the region's weakening economic performance and concerns that GPs’ short-term investment horizons are not beneficial to the broader...
Indian GPs see opportunity amidst chaos - AVCJ Forum
Indian GPs expect the current vintage of country funds to enjoy a favorable investment climate as valuations moderate and competition for deals eases, even though they acknowledge that LP sentiment in many cases remains weak.
Kedaara closes debut India fund at $540m, rupee vehicle to follow
Kedaara Capital, a private equity firm led by former Temasek India head Manish Kejriwal, has reached a final close on its debut fund at $540 million. A rupee-denominated fund, which will co-invest alongside the US dollar fund on a pro rata basis, is in...
H&Q invests $90m Monster-owned JobKorea
H&Q Korea has agreed to buy a 49.9% interest in JobKorea, the South Korean operation of Monster Worldwide, for an aggregate purchase price of $90 million. Monster will retain management control of the business, with H&Q supporting regional expansion efforts.
IDFC Alternatives buys stake in India commodities exchange
IDFC Alternatives has acquired a 5% stake in National Commodity and Derivatives Exchange (NCDEX), India’s largest agricultural commodity derivatives exchange, from Jaypee Financial Services for INR456 million ($7.3 million).
Investment: Southeast Asia's family footholds
By most measures, Southeast Asia is under-penetrated by private equity. If deal flow expectations are to be met, investors must tap local networks for openings in and around the family conglomerates
Asia fundraising: Size matters?
While a select group of GPs are able to raise large funds at short order in Asia, the small and mid-cap space is hollowing out. It is in parts cyclical and a function of broader changes in the post-financial crisis LP base
Exits: Stuck in China
The weak IPO market has left many China PE firms holding assets for longer than expected. While growth deals will remain dominant, there will be change in how and with whom they are done
CNEI invests $25.4m in Chinese drug developer
China New Enterprise Investment (CNEI) has acquired a 17% stake in Fudan-Zhangjiang Bio-Pharmaceutical (FDZJ) for $25.4 million, becoming the second-largest shareholder in the Shanghai based bio-pharmaceutical firm.